Ionis Pharmaceuticals
IONS
369 hedge funds and large institutions have $7.3B invested in Ionis Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 124 increasing their positions, 119 reducing their positions, and 69 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 119
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less call options, than puts
Call options by funds: $94.6M | Put options by funds: $97.4M
3.45% less ownership
Funds ownership: 90.24% → 86.79% (-3.4%)
7% less funds holding
Funds holding: 396 → 369 (-27)
10% less capital invested
Capital invested by funds: $8.14B → $7.3B (-$833M)
39% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 69
Top Buyers
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$59.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$47.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$45.6M |
| 4 |
Two Sigma Investments
New York
|
-$42.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$41.9M |
IONS Hedge Fund Activity: Q3 2019 in Review
369 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2019, worth a combined $7.3B — down 10% from $8.14B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of IONS and 42 opened new positions — a net loss of 27 holders — while 119 trimmed existing stakes and 124 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $61M. The largest seller was Goldman Sachs, cutting an estimated $59.9M.
- 369 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2019, down from 396 in Q2 2019.
- Funds reported $7.3B of Ionis Pharmaceuticals stock for Q3 2019, down 10% quarter-over-quarter.
- 42 funds opened new Ionis Pharmaceuticals positions in Q3 2019 and 69 closed out, a net change of -27 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2019 was BVF Inc, an estimated $61M added.
- The largest Ionis Pharmaceuticals seller in Q3 2019 was Goldman Sachs, an estimated $59.9M sold.
Based on aggregated 13F filings for Q3 2019.